Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,703 | 310 | 3,337 |
| Samples | 407 | 58 | 341 |
| Peptides | 284 | 41 | 253 |
Function
ERG · ETS transcription factor ERG
This gene encodes a member of the erythroblast transformation-specific (ETS) family of transcriptions factors. All members of this family are key regulators of embryonic development, cell proliferation, differentiation, angiogenesis, inflammation, and apoptosis. The protein encoded by this gene is mainly expressed in the nucleus. It contains an ETS DNA-binding domain and a PNT (pointed) domain which is implicated in the self-association of chimeric oncoproteins. This protein is required for platelet adhesion to the subendothelium, inducing vascular cell remodeling. It also regulates hematopoesis, and the differentiation and maturation of megakaryocytic cells. This gene is involved in chromosomal translocations, resulting in different fusion gene products, such as TMPSSR2-ERG and NDRG1-ERG in prostate cancer, EWS-ERG in Ewing's sarcoma and FUS-ERG in acute myeloid leukemia. More than two dozens of transcript variants generated from combinatorial usage of three alternative promoters and multiple alternative splicing events have been reported, but the full-length nature of many of these variants has not been determined. [provided by RefSeq, Apr 2014].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000288319 | P11308 | 411 | 235 |
| ENST00000417133 | P11308-3 | 387 | 233 |
| ENST00000398919 | P11308-3 | 386 | 232 |
| ENST00000398910 | A8MZ24* | 380 | 227 |
| ENST00000398907 | A8MX39* | 375 | 222 |
| ENST00000398911 | P11308-1 | 372 | 226 |
| ENST00000442448 | P11308-1 | 370 | 224 |
| ENST00000398905 | A0A0D4D914* | 368 | 222 |
| ENST00000453032 | A0A0C4DG41* | 326 | 188 |
| ENST00000398897 | P11308-2 | 310 | 180 |
| ENST00000262186 | Q12809 | 11 | 6 |
| ENST00000330883 | Q12809-2 | 7 | 4 |
Gene Properties
Recurrent Mutations
All 235 amino-acid changes on canonical ENST00000288319 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ERG · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ERG – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 8/210 4% | 63/1899 3% |
| Endometrial Carcinoma | 1/42 2% | 14/612 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Colorectal Carcinoma | 8/143 6% | 52/3239 2% |
| Gastric Carcinoma | 1/74 1% | 27/1809 1% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 12/1390 1% |
| Other Solid Cancers | 1/94 1% | 17/1515 1% |
| Bladder Carcinoma | 1/58 2% | 9/956 1% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Hepatocellular Carcinoma | 0/46 0% | 17/2210 1% |
| B-Lymphoblastic Leukemia | 0/55 0% | 19/2640 1% |
| Biliary Tract Carcinoma | 1/54 2% | 6/950 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Glioma | 0/52 0% | 14/2127 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Thyroid Gland Carcinoma | 4/45 9% | 5/1592 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 12/2550 0% |
| Breast Carcinoma | 1/144 1% | 17/3264 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 10/2534 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
Mutation Distribution
Where ERG is mutated · all tissues, split by cell line vs tissue
How many mutations in ERG were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,703 mutations in ERG
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|